Insurance Delays in Initiation of Tumor Necrosis Factor Inhibitors in Children With Juvenile Idiopathic Arthritis

Jordan E. Roberts, Mary Beth F. Son(Boston Children's Hospital), Mary D. Fan(University of Washington)

JAMA Network Open

April 21, 2022

10.1001/jamanetworkopen.2022.8330

Cited by 4

Related Papers

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

|New England Journal of Medicine|2020|2.7k

Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19

|JAMA|2021|852

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1

|Arthritis & Rheumatology|2020|537

Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series

|Arthritis & Rheumatism|2010|465

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2

|Arthritis & Rheumatology|2020|415